Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer Conference

related documents

• A Phase 2 biomarker-enriched study of evofosfamide (TH-302) in patients with advanced melanoma.  Conference Paper
• A phase I study of BI 853520, an inhibitor of focal adhesion kinase (FAK), in patients with advanced or metastatic solid tumors.  Conference Paper
• A phase I/II clinical trial of veliparib (ABT-888) and radiation followed by maintenance therapy with veliparib and temozolomide in patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG): A Pediatric Brain Tumor Consortium Interim Report of Phase I Study.  Conference Paper
• A phase I/II study of ipilimumab in women with metastatic or recurrent cervical carcinoma: A study of the Princess Margaret and Chicago N01 Consortia.  Conference Paper
• A phase III study of the impact of a physical activity program on disease-free survival in patients with high-risk stage II or stage III colon cancer: A randomized controlled trial (NCIC CTG CO.21).  Conference Paper
• A phase Ib study of selumetinib in patients (pts) with previously untreated metastatic Non-Small Cell Lung Cancer (NSCLC) receiving standard chemotherapy: NCIC Clinical Trials Group IND.215. NCT01783197.  Conference Paper
• Blood and urine markers of metabolic dysfunction in colorectal cancer: a pilot study.  Conference Paper
• Can oncology readmissions be reduced? The Cleveland Clinic experience.  Conference Paper
• Cancer-related cognitive dysfunction (CRCD) and psychosocial development in young adult cancer survivors.  Conference Paper
• Correlation between the DCIS Score and traditional clinicopathologic features in the prospectively-designed Ontario population-based validation study.  Conference Paper
• Evaluation of clinical and histological criteria and outcome in management of hereditary non-polyposis colorectal carcinoma (HNPCC).  Conference Paper
• Expression of thyroid hormone receptor alpha (THR alpha) isoforms in triple negative breast cancer (TNBC)  Conference Paper
• Externally validated improved 5-factor prognostic model in patients (pts) receiving salvage systemic therapy for advanced urothelial carcinoma (UC).  Conference Paper
• Final follow-up (f/u) results from RADIANT: A randomized double blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection in patients (pts) with stage IB-IIIA EGFR positive (IHC/FISH) non-small cell lung cancer (NSCLC).  Conference Paper
• Gemcitabine and platinum (GC) chemotherapy alone or with a taxane (GC-T) as first-line therapy for urothelial cancer (UC): A meta-analysis.  Conference Paper
• Hepatitis B virus screening before adjuvant chemotherapy in patients with early stage breast cancer: A cost-effectiveness analysis.  Conference Paper
• Ibrutinib combined with bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): First results from a randomized, double-blind, placebo-controlled, phase III study.  Conference Paper
• Impact of rolapitant on quality of life (QoL) in patients (pts) receiving highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC)  Conference Paper
• Improving fitness after childhood cancer: A novel exercise clinic for pediatric oncology patients.  Conference Paper
• Incidence of ipsilateral recurrence after open or thoracoscopic resection of colorectal lung metastases.  Conference Paper
• Meta-analysis of the impact of single agent daily prednisone on outcomes and toxicities in metastatic castration-resistant prostate cancer (mCRPC).  Conference Paper
• Modifiable metabolic markers c-peptide (C-PEP), highly sensitive c-reactive protein (hsCRP), leptin (LEP)] and lung cancer (LC) risk: A matched case-control study nested in the prostate, lung, colorectal and ovarian (PLCO) cancer screening study.  Conference Paper
• NCIC CTG IND.206: A phase II umbrella trial of sunitinib (S) or temsirolimus (T) in advanced rare cancers.  Conference Paper
• Outcome of neurofibromatosis type 1 patients treated with first line vinblastine for optic pathway gliomas: A Canadian multicenter study.  Conference Paper
• Phase 1 study with expansion cohorts of cabozantinib (C) + abiraterone (A) in metastatic castration resistant prostate cancer (mCRPC): Investigator-sponsored study.  Conference Paper
• Phase II study of individualized sunitinib as first-line therapy for metastatic renal cell cancer (mRCC).  Conference Paper
• Phase III randomized trial of standard fractionation radiotherapy (SFX) with concurrent cisplatin (CIS) versus accelerated fractionation radiotherapy (AFX) with panitumumab (PMab) in patients (pts) with locoregionally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): NCIC Clinical Trials Group HN.6 trial.  Conference Paper
• Physicians' attitudes toward systematic symptom assessment and management: Results from all regional cancer centres in Ontario (Canada).  Conference Paper
• Quality of life (QOL) in a phase III randomized trial of standard fractionation radiotherapy (SFX) with concurrent cisplatin (CIS) versus accelerated fractionation radiotherapy (AFX) with panitumumab (PMab) in patients (pts) with locoregionally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): NCIC Clinical Trials Group HN.6 (NCT00820248).  Conference Paper
• Recurrence score and clinicopathologic characteristics of TAILORx participants by race and ethnicity.  Conference Paper
• Risk after local excision alone for DCIS patients.  Conference Paper
• The role of PET-CT in treatment decision making for women with locally advanced cervical cancer.  Conference Paper
• The role of biomarkers in improving clinical trial success: A study of 1,079 oncology drugs.  Conference Paper
• Trends in demographics, incidence, and survival in children, adolescents and young adults (AYA) with melanoma: A Surveillance, Epidemiology and End Results (SEER) population-based analysis  Conference Paper
• Tumor treating fields (TTFields): A novel treatment modality added to standard chemo- and radiotherapy in newly diagnosed glioblastoma—First report of the full dataset of the EF14 randomized phase III trial.  Conference Paper